The middle layer of the eye, known as the uvea, becomes inflamed when someone has eye inflammation or uveitis.

An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.

Immunotherapy. 2013;5(1):91-102. The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject ...

After having surgery for uveitis-associated cataracts, patients who had experienced more uveitis attacks required longer ...

Company continues focus on development of subcutaneous lonigutamab in thyroid eye disease, with initiation of Phase 3 program on schedule for Q1 2025 $562.4 million in cash, cash equivalents, and ...

Discover tattoo-associated uveitis, a rare eye inflammation condition linked to delayed immune reactions to tattoo ink, and ...